Dorzagliatin: First Approval

Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists

(2022) Yixin Ren et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

115-LB: Dorzagliatin Showed Sustained Remission in an Observational Study after Discontinuation of Treatment in T2D Patients Who Achieved Good Glycemic Control with Dorzagliatin Monotherapy

(2022) JIAOE ZENG et al.   DIABETES

117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient—A Post Hoc Analysis of Dorzagliatin

(2022) LINGGE FENG et al.   DIABETES

261-OR: Dorzagliatin, a Dual-Acting Glucokinase Activator. Improves Insulin Secretion and Glucose Sensitivity in Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY)

(2022) ELAINE CHOW et al.   DIABETES

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

(2022) Dalong Zhu et al.   NATURE MEDICINE

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

(2022) Wenying Yang et al.   NATURE MEDICINE

117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function

(2021) LI CHEN et al.   DIABETES

Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator

(2021) Jia Miao et al.   CTS-Clinical and Translational Science

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments

(2020) Konstantinos A. Toulis et al.   DRUGS

The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans

(2019) Franz M. Matschinsky et al.   Frontiers in Physiology

Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

(2018) Xiao-Xue Zhu et al.   DIABETES OBESITY & METABOLISM

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

(2018) Dalong Zhu et al.   Lancet Diabetes & Endocrinology

Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

(2016) Dongyang Liu et al.   CLINICAL PHARMACOKINETICS